TSLA
Tesla
-- 230.160 NVDA
NVIDIA
-- 109.830 PLTR
Palantir
-- 77.930 AAPL
Apple
-- 223.940 MSTR
Strategy
-- 243.750 
NEWS
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology™ platform trigger targeted immune responses
Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virus
Evaxion is advancing these new findings to develop a multi-component CMV vaccine candidate
About 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in developed countries. No approved CMV vaccine exists today
Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virus
Evaxion is advancing these new findings to develop a multi-component CMV vaccine candidate
About 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in developed countries. No approved CMV vaccine exists today
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment